Not a weapons cache. Not a staging area for mass deployment.
A research lab. Development phase. Whatever they’re building here, it isn’t finished yet.
I move past her, keeping low, checking sight lines even though the facility shows every sign of evacuation. Empty workstations. Overturned chairs. Equipment left running on standby, humming softly in the silence. Old habits don’t care about evidence of abandonment. Old habits are why I’m still breathing.
The containers are labeled with serial numbers and batch codes. I photograph the nearest cluster, then crouch to examine the markings more closely.
BIOLOGICAL COMPUTATION COMPONENT
ORGANIC NEURAL TISSUE
PHASE THREE READY
The words don’t make sense. Biological computation. Organic neural tissue. I read them twice, waiting for meaning to click into place. It doesn’t.
“Small quantities,” I say. “Each container holds maybe a hundred units. This isn’t manufacturing capacity. It’s R&D.”
“So they’re still developing it? Whatever it is?” Cassie moves to the next row, her footsteps careful on the frost-slicked concrete. “Still trying to get it to work.”
“Looks like.”
The observation should be reassuring. Whatever nightmare Phoenix is planning, it’s not ready yet. But the scale of the operation—the investment, the infrastructure, the clinical precision of every detail—tells a different story. This isn’t aproject that might fail. This is a project that’s being refined until it succeeds.
I move deeper into the lab. Workstations line the walls—microscopes with automated focusing systems, centrifuges still loaded with sample vials, equipment I can name but couldn’t operate without training. Papers scattered across desks in patterns that suggest sudden departure rather than careful organization. Coffee cups frozen solid, the liquid transformed into brown ice sculptures.
They left in a hurry. But not today. The frost on the mugs is old, the papers stiff with moisture that condensed and froze over time. Days, maybe weeks.
Something scared them so badly that they abandoned a multi-million-dollar research facility. And I don’t think it was us.
Cassie follows, her footsteps careful on the concrete floor. She’s found her rhythm—staying close enough to communicate in whispers, far enough not to crowd my firing arc if I need to engage a threat. Partnership in motion. The kind of coordination that used to take weeks to develop with trained operators.
She’s not trained. She’s just paying attention.
“Here.” She’s stopped at a filing cabinet, with drawers half-open, as if someone had started grabbing files and then given up. “Trial data.”
I cross to her position, keeping my light angled low to preserve our night vision. The folders are thick, densely packed with charts and tables, and the kind of clinical shorthand that turns human suffering into spreadsheet entries. Medical terminology mixed with statistical analysis. The language of research divorced from the reality of what was being researched.
Meridian Pharmaceuticals - ML-273 Phase I Trial. Cancer Treatment Efficacy Study
“Cancer treatment,” Cassie reads, her voice carefully neutral. “That’s what they told the subjects.”
“That’s what they told everyone.” I flip through the pages, scanning for the methodology section. “Look at this. The formulation wasn’t targeting tumors. It was targeting neural tissue. Brain chemistry. Synaptic structures.”
“So the cancer treatment was a cover?”
“The cancer treatment was a lie.”
The trial data reads like a horror novel written in clinical notation. Each entry follows the same format—subject number, baseline assessment, treatment protocol, outcome. The outcomes are almost uniformly terrible.
Subject 7: Mortality. Neural hemorrhage. Time from treatment to expiration: 72 hours.
Subject 12: Mortality. Systemic rejection. Time from treatment to expiration: 96 hours.
Subject 19: Mortality. Cognitive collapse. Subject remained conscious but non-responsive for 48 hours prior to cardiac failure.
Subject 23: Mortality. Organ failure secondary to neural degradation. Time from treatment to expiration: 31 hours.
Row after row. Death after death. Failures marked in cold shorthand like they were discussing crop yields instead of human beings dying in confused agony while their brains turned against them.
